Clinuvel Pharmaceuticals Limited (CUV.AX)
AUD 11.42
(-1.47%)
AUD 11.42
(-1.47%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -182.98 Million AUD | -700.22% |
| 2023 | -22.86 Million AUD | 12.56% |
| 2022 | -26.15 Million AUD | 27.02% |
| 2021 | -35.83 Million AUD | -47.28% |
| 2020 | -24.33 Million AUD | 54.8% |
| 2019 | -53.83 Million AUD | -48.73% |
| 2018 | -36.19 Million AUD | -52.4% |
| 2017 | -23.75 Million AUD | -71.56% |
| 2016 | -13.84 Million AUD | -30.95% |
| 2015 | -10.57 Million AUD | 27.71% |
| 2014 | -14.62 Million AUD | -16.36% |
| 2013 | -12.56 Million AUD | 1.18% |
| 2012 | -12.71 Million AUD | -4.44% |
| 2011 | -12.17 Million AUD | 37.27% |
| 2010 | -19.41 Million AUD | 10.57% |
| 2009 | -21.71 Million AUD | 15.69% |
| 2008 | -25.75 Million AUD | 23.9% |
| 2007 | -33.84 Million AUD | -293.24% |
| 2006 | -8.6 Million AUD | -80.69% |
| 2005 | -4.76 Million AUD | 13.1% |
| 2004 | -5.48 Million AUD | -109.83% |
| 2003 | -2.61 Million AUD | 40.83% |
| 2002 | -4.41 Million AUD | 36.77% |
| 2001 | -6.98 Million AUD | 11.94% |
| 2000 | -7.92 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -37.74 Million AUD | 0.0% |
| 2024 Q4 | -182.98 Million AUD | 0.0% |
| 2024 FY | -182.98 Million AUD | -700.22% |
| 2023 FY | -22.86 Million AUD | 12.56% |
| 2023 Q2 | -139.56 Million AUD | 0.0% |
| 2023 Q4 | -22.86 Million AUD | 0.0% |
| 2022 FY | -26.15 Million AUD | 27.02% |
| 2022 Q4 | -26.15 Million AUD | 0.0% |
| 2022 Q2 | -97.82 Million AUD | 0.0% |
| 2021 Q4 | -35.83 Million AUD | 0.0% |
| 2021 FY | -35.83 Million AUD | -47.28% |
| 2021 Q2 | -71.54 Million AUD | 0.0% |
| 2020 Q4 | -24.33 Million AUD | 0.0% |
| 2020 Q2 | -57.12 Million AUD | 0.0% |
| 2020 FY | -24.33 Million AUD | 54.8% |
| 2019 FY | -53.83 Million AUD | -48.73% |
| 2019 Q2 | -42.82 Million AUD | 0.0% |
| 2019 Q4 | -53.83 Million AUD | 0.0% |
| 2018 FY | -36.19 Million AUD | -52.4% |
| 2018 Q4 | -36.19 Million AUD | 0.0% |
| 2018 Q2 | -27.93 Million AUD | 0.0% |
| 2017 Q4 | -23.75 Million AUD | 0.0% |
| 2017 Q2 | -19.55 Million AUD | 0.0% |
| 2017 FY | -23.75 Million AUD | -71.56% |
| 2016 Q4 | -13.84 Million AUD | 0.0% |
| 2016 FY | -13.84 Million AUD | -30.95% |
| 2016 Q2 | -7.49 Million AUD | 0.0% |
| 2015 Q2 | -11.97 Million AUD | 0.0% |
| 2015 FY | -10.57 Million AUD | 27.71% |
| 2015 Q4 | -10.57 Million AUD | 0.0% |
| 2014 FY | -14.62 Million AUD | -16.36% |
| 2014 Q2 | -9.74 Million AUD | 0.0% |
| 2014 Q4 | -14.62 Million AUD | 0.0% |
| 2013 Q4 | -12.56 Million AUD | 0.0% |
| 2013 FY | -12.56 Million AUD | 1.18% |
| 2013 Q3 | -12.56 Million AUD | -26.58% |
| 2013 Q2 | -9.92 Million AUD | 0.0% |
| 2013 Q1 | -9.92 Million AUD | 21.93% |
| 2012 FY | -12.71 Million AUD | -4.44% |
| 2012 Q4 | -12.71 Million AUD | 0.0% |
| 2011 FY | -12.17 Million AUD | 37.27% |
| 2011 Q4 | -12.17 Million AUD | 0.0% |
| 2010 FY | -19.41 Million AUD | 10.57% |
| 2010 Q4 | -19.41 Million AUD | 0.0% |
| 2009 FY | -21.71 Million AUD | 15.69% |
| 2009 Q4 | -21.71 Million AUD | 0.0% |
| 2008 FY | -25.75 Million AUD | 23.9% |
| 2008 Q4 | -25.75 Million AUD | 0.0% |
| 2007 Q4 | -33.84 Million AUD | 0.0% |
| 2007 FY | -33.84 Million AUD | -293.24% |
| 2006 FY | -8.6 Million AUD | -80.69% |
| 2006 Q4 | -8.6 Million AUD | 0.0% |
| 2005 FY | -4.76 Million AUD | 13.1% |
| 2005 Q4 | -4.76 Million AUD | 0.0% |
| 2004 Q4 | -5.48 Million AUD | 0.0% |
| 2004 FY | -5.48 Million AUD | -109.83% |
| 2003 Q4 | -2.61 Million AUD | 0.0% |
| 2003 FY | -2.61 Million AUD | 40.83% |
| 2002 FY | -4.41 Million AUD | 36.77% |
| 2002 Q4 | -4.41 Million AUD | 0.0% |
| 2001 FY | -6.98 Million AUD | 11.94% |
| 2000 FY | -7.92 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | -21551.033% |
| Acrux Limited | -1.45 Million AUD | -12450.664% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -9934.525% |
| Biome Australia Limited | -1.56 Million AUD | -11608.975% |
| BTC Health Limited | -2.02 Million AUD | -8949.192% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -5893.732% |
| CSL Limited | 15.76 Billion AUD | 101.161% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | -34.052% |
| Noxopharm Limited | -2.31 Million AUD | -7787.692% |
| PharmAust Limited | -9.71 Million AUD | -1783.741% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | -2793.628% |
| Prescient Therapeutics Limited | -10.16 Million AUD | -1700.592% |
| PYC Therapeutics Limited | -65.76 Million AUD | -178.26% |
| Race Oncology Limited | -17.18 Million AUD | -964.579% |
| Starpharma Holdings Limited | -19.83 Million AUD | -822.694% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | -868.258% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | -130.731% |
| Memphasys Limited | 4.13 Million AUD | 4524.963% |
| Nyrada Inc. | -4.76 Million AUD | -3736.744% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -18532.256% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | -72.97% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -25689.109% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 3711.145% |
| Patrys Limited | -2.24 Million AUD | -8066.728% |
| Dimerix Limited | -21.99 Million AUD | -732.078% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | -970.485% |
| Orthocell Limited | -19.92 Million AUD | -818.399% |
| Imugene Limited | -91.56 Million AUD | -99.855% |
| Cynata Therapeutics Limited | -6.2 Million AUD | -2848.854% |
| Immutep Limited | -122.18 Million AUD | -49.758% |
| Arovella Therapeutics Limited | -12.71 Million AUD | -1339.223% |
| Alterity Therapeutics Limited | -12.47 Million AUD | -1366.274% |
| Nanollose Limited | -96.22 Thousand AUD | -190067.511% |
| Invex Therapeutics Ltd | -6.02 Million AUD | -2937.122% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -3593.65% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -14676.111% |
| Biotron Limited | -386.06 Thousand AUD | -47298.046% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | -885.132% |
| Tissue Repair Ltd | -16.44 Million AUD | -1012.999% |
| AnteoTech Limited | -5 Million AUD | -3558.659% |
| Hexima Limited | -2.22 Million AUD | -8119.726% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | -940.803% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -5288.147% |
| Avecho Biotechnology Limited | -5.32 Million AUD | -3333.67% |
| Actinogen Medical Limited | -9.13 Million AUD | -1903.892% |
| Immuron Limited | -11.48 Million AUD | -1493.448% |
| Argenica Therapeutics Limited | -15.91 Million AUD | -1049.957% |